comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 20:46:48 - browse：1

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Physician executives need more than on

hotspot

WSS

Colorectal cancer study finds potential in overlooked immune cell

Phenylephrine and the overlooked value of the placebo effect

Chemotherapy drug shortage eases slightly but still widespread

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Bristol 'take

Analysis of telehealth claims data suggest service duplication

leisure time

comprehensive

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Histogen: Failed biotech offers rare public look inside

As demand for Covid shots wanes, Moderna seeks its next success

Was Amgen transparent enough on FDA's concern on cancer drug?

At least 13 dead in Texas as scorching temps continue

Liquid biopsy for lung cancer is launched by Delfi

Activists slam private health insurers over coverage restrictions

A virus, fished out of a lake, may have saved a man’s life

Cancer drug shortages should be causing more outrage

Zapping the brain for stroke rehab: Pivotal clinical trial begins

explore

Why Charlie Gard's case is so disturbing to Americans

Histogen: Failed biotech offers rare public look inside

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

3 questions for the future of Biden's cancer moonshot

Why age limits for politicians are a terrible idea

‘The Bear’ and hospitality in hospitals

explore

hotspot

hotspot

hotspot